Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Conditions
Brief summary
Cilengitide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving cilengitide together with temozolomide and radiation therapy may kill more tumor cells. This randomized phase I/II trial is studying the side effects and best dose of cilengitide when given together with temozolomide and radiation therapy and to compare how well they work in treating patients with newly diagnosed glioblastoma multiforme
Detailed description
PRIMARY OBJECTIVES: I. To assess the safety profile of EMD 121974 (cilengitide) when administered as a one-hour infusion twice a week concurrently with concomitant and adjuvant temozolomide with radiation therapy for newly diagnosed glioblastoma multiforme. (Safety Run-In) II. To estimate overall survival in newly diagnosed patients with glioblastoma multiforme treated with EMD 121974 concurrently with concomitant and adjuvant temozolomide with radiation therapy. (Phase II) SECONDARY OBJECTIVES: I. To estimate and compare overall survival between a low dose treatment group and a high dose treatment group in newly diagnosed patients with glioblastoma multiforme treated with EMD 121974 concurrently with concomitant and adjuvant temozolomide with radiation therapy. (Phase II) II. To determine the toxicity of EMD 121974 (cilengitide) when it is administered in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme. (Phase II) III. To evaluate the molecular profile of individual patients and correlate molecular expression profiles with clinical outcomes. (Phase II) IV. To characterize tumor blood volume, tumor blood flow, and permeability ratios using perfusion MR in newly diagnosed glioblastoma multiforme and follow these parameters during treatment with EMD 121974 (cilengitide). (Phase II) OUTLINE: This is an open-label, multicenter, safety run-in study of cilengitide followed by a randomized phase II study. Safety Run-In: INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6. MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of cilengitide (3 Pre-defined study dose levels are defined as: 500, 1000 and 2000mg). The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity. If no MTD (maximum tolerable dose) is defined through three steps of the dose escalation process, we will pursue the phase II safety/efficacy study with randomized treatment allocation. Patients will be randomized into one of two pre-specified treatment dosage arms, 500mg group or 2000mg group. PHASE II: Patients are stratified according to age (50 and under vs over 50), Karnofsky performance score (60%-80% vs 90%-100%), and tumor status (measurable vs nonmeasurable). Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive radiotherapy and temozolomide as in safety run-in initiation course and cilengitide at the lower dose as in safety run-in initiation and maintenance courses. ARM II: Patients receive radiotherapy and temozolomide as in safety run-in initiation course and cilengitide at the higher dose as in safety run-in initiation and maintenance courses. Patients are followed every 2 months. PROJECTED ACCRUAL: A total of 9-112 patients (9-18 for safety run-in and 94 \[47 per treatment arm\] for phase II) will be accrued for this study within 1.5-37 months
Interventions
DRUGcilengitide
Given IV
DRUGtemozolomide
Given orally
RADIATIONradiation therapy
Undergo radiotherapy
OTHERlaboratory biomarker analysis
Correlative studies
OTHERpharmacological study
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme) * Patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowed * Patients must have a Karnofsky performance status \>= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others) * Absolute neutrophil count \>= 1500/mm\^3 * Platelets \>= 100,000/mm\^3 * Creatinine =\< 1.5 mg/dl or creatinine clearance \>= 60 mL/min * Total bilirubin =\< 1.5 mg/dl * Transaminases =\< 4 times above the upper limits of the institutional normal * Patients must be able to provide written informed consent * Patients must have recovered from the immediate post-operative period and be maintained on a stable corticosteroid regimen (no increase for 5 days) prior to the start of treatment * Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception; women of childbearing potential must have a negative pregnancy test * Patients must have a Mini Mental State Exam score of \>= 15 * Patients must have tumor tissue form completed and signed by a pathologist
Exclusion criteria
* Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety * Patients who are pregnant or breast-feeding * Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) * Patients with a concurrent or prior malignancy are ineligible unless they are patients with curatively treated carcinoma-in-situ or basal cell carcinoma of the skin; patients who have been free of disease (any prior malignancy) for \>= five years are eligible for this study * Patients who are unable to undergo an MRI evaluation * Patients with a history of wound-healing disorders, advanced coronary disease, or with a recent history (# 1 year) of peptic ulcer disease are ineligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicities of EMD + RT and TMZ | 10 weeks | pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I) DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting. Nonhematological toxicities Grades 3-4 severity (except nausea and vomiting without sufficient antiemetic prophylaxis) |
| Maximum Tolerated or Tolerable Dose (MTD) - 3 Pre-defined Doses | 10 weeks | pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review any dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (safety run-in) DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting. cohorts at these 3 defined doses: 500mg, 1000mg and 2000mg MTD defined as: dose producing DLT in 2 out of 6 patients or dose level below the dose which produced DLT in \>/= 2 out of 3 patients, or in \>/= 3 out of 6 patients If no MTD (maximum tolerable dose) was defined through 3 steps of dose escalation, phase 2 will proceed with a randomized treatment allocation of the two pre-specified dosage arms: low dose; 500mg and high dose; 2000mg |
| Overall Survival (Phase II) | up to 36 months | The overall survival is calculated from time of histological diagnosis to death occurance - median based on all 112 patients, all dose levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival Based on Dose Level - Phase 2 | Up to 3 years | survival calculated from date of initial histologic diagnosis and occurence of death. Pts at 500mg dose compared against Pts treated at 2000mg dose. Calculated using median |
| Frequency of Hematologic and Nonhematologic Adverse Events | Up to 1 year | The proportion of patients with grade 3 and grade 4 hematologic and non hematologic adverse events per CTCAE 4.0 |
Countries
United States
Participant flow
Recruitment details
Study sponsored by CTEP and conducted by New Approaches to Brain Tumor Therapy (NABTT). Pts accrued between April 2005 and December 2007. Pts were accrued from 11 Cancer Centers nation wide, in an outpatient setting. All pts had undergone previous surgery and had diagnosis of glioblastoma
Participants by arm
| Arm | Count |
|---|---|
| Arm 1 - Safety Run In INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.
MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Doses of cilengitide: 500mg, 1000mg and 2000mg
Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study
cilengitide: Given IV
temozolomide: Given orally
radiation therapy: Undergo radiotherapy
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies | 18 |
| Arm 2 - Phase 2 (Treatment 1) INITIATION COURSE: Patients receive cilengitide (500mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.
MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide (500mg) IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Doses of cilengitide: 500mg, 1000mg and 2000mg
Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study
cilengitide: Given IV
temozolomide: Given orally
radiation therapy: Undergo radiotherapy
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies | 46 |
| Arm 3 - Phase 2 (Treatment 2) INITIATION COURSE: Patients receive cilengitide (2000mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.
MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide (2000mg) IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Doses of cilengitide: 500mg, 1000mg and 2000mg
Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study
cilengitide: Given IV
temozolomide: Given orally
radiation therapy: Undergo radiotherapy
laboratory biomarker analysis: Correlative studies
pharmacological study: Correlative studies | 48 |
| Total | 112 |
Baseline characteristics
| Characteristic | Arm 1 - Safety Run In | Arm 2 - Phase 2 (Treatment 1) | Arm 3 - Phase 2 (Treatment 2) | Total |
|---|---|---|---|---|
| Age, Continuous | 55.6 years | 56.3 years | 54.9 years | 55.5 years |
| Corticosteroid Therapy missing data | 1 participants | 0 participants | 1 participants | 2 participants |
| Corticosteroid Therapy No | 4 participants | 13 participants | 11 participants | 28 participants |
| Corticosteroid Therapy Yes | 13 participants | 33 participants | 36 participants | 82 participants |
| Karnofsky Performance Status 100 | 4 participants | 8 participants | 15 participants | 27 participants |
| Karnofsky Performance Status 60 | 0 participants | 2 participants | 2 participants | 4 participants |
| Karnofsky Performance Status 70 | 3 participants | 6 participants | 6 participants | 15 participants |
| Karnofsky Performance Status 80 | 5 participants | 3 participants | 7 participants | 15 participants |
| Karnofsky Performance Status 90 | 6 participants | 27 participants | 18 participants | 51 participants |
| MGMT Statis methylated | 3 participants | 11 participants | 7 participants | 21 participants |
| MGMT Statis unknown | 6 participants | 14 participants | 23 participants | 43 participants |
| MGMT Statis unmethylated | 9 participants | 21 participants | 18 participants | 48 participants |
| Sex: Female, Male Female | 9 Participants | 18 Participants | 19 Participants | 46 Participants |
| Sex: Female, Male Male | 9 Participants | 28 Participants | 29 Participants | 66 Participants |
| Surgical Proceedure biopsy | 6 participants | 10 participants | 9 participants | 25 participants |
| Surgical Proceedure craniotomy | 12 participants | 35 participants | 39 participants | 86 participants |
| Surgical Proceedure other | 0 participants | 1 participants | 0 participants | 1 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 11 / 52 | 0 / 6 | 14 / 54 |
| serious Total, serious adverse events | 0 / 52 | 0 / 6 | 1 / 54 |
Outcome results
Primary
Dose Limiting Toxicities of EMD + RT and TMZ
pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I) DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting. Nonhematological toxicities Grades 3-4 severity (except nausea and vomiting without sufficient antiemetic prophylaxis)
Time frame: 10 weeks
Population: at least 3 pts per cohort will be used to review DLT rate for dose escalation in stepwise fashion. we will enroll 6 pts to ensure that 3 pts are evaluable due to high drop out rate.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm 1 500mg (Safety Run In) | Dose Limiting Toxicities of EMD + RT and TMZ | 0 participants |
| ARM 2 1000mg (Safety run-in) | Dose Limiting Toxicities of EMD + RT and TMZ | 0 participants |
| Arm 3 2000mg (Safety Run-In) | Dose Limiting Toxicities of EMD + RT and TMZ | 0 participants |
Primary
Maximum Tolerated or Tolerable Dose (MTD) - 3 Pre-defined Doses
pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review any dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (safety run-in) DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting. cohorts at these 3 defined doses: 500mg, 1000mg and 2000mg MTD defined as: dose producing DLT in 2 out of 6 patients or dose level below the dose which produced DLT in \>/= 2 out of 3 patients, or in \>/= 3 out of 6 patients If no MTD (maximum tolerable dose) was defined through 3 steps of dose escalation, phase 2 will proceed with a randomized treatment allocation of the two pre-specified dosage arms: low dose; 500mg and high dose; 2000mg
Time frame: 10 weeks
Population: at least 3 pts per cohort will be used to review MTD rate for dose escalation in stepwise fashion of 3 defined doses: 500, 1000 and 2000mg. We will enroll 6 pts to ensure that 3 pts are evaluable due to high drop out rate.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm 1 500mg (Safety Run In) | Maximum Tolerated or Tolerable Dose (MTD) - 3 Pre-defined Doses | NA mg |
Primary
Overall Survival (Phase II)
The overall survival is calculated from time of histological diagnosis to death occurance - median based on all 112 patients, all dose levels
Time frame: up to 36 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm 1 500mg (Safety Run In) | Overall Survival (Phase II) | 19.7 months |
Comparison: Primary endpoint death - defined from histological diagnosis to death. we assume pt in the study will have overall failure rate of 0.56 per person-year of f/up, a 30% reduction compared to hazard rate of 0.8 per person-year in historical NABTT database. Expected hazard ratio is 0.7 and cohort will produce 63 events among total of 94 pt planned f/up. One-sided test, have 95% power to detect observed ratio of 0.7 at alpha level of 0.1, or we have 88% power at alpha of 0.5 statistical significantp-value: 0.000195% CI: [0.3, 0.5]Log Rank
Secondary
Frequency of Hematologic and Nonhematologic Adverse Events
The proportion of patients with grade 3 and grade 4 hematologic and non hematologic adverse events per CTCAE 4.0
Time frame: Up to 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm 1 500mg (Safety Run In) | Frequency of Hematologic and Nonhematologic Adverse Events | 48 Number of grade 3 or 4 events |
| ARM 2 1000mg (Safety run-in) | Frequency of Hematologic and Nonhematologic Adverse Events | 35 Number of grade 3 or 4 events |
Secondary
Overall Survival Based on Dose Level - Phase 2
survival calculated from date of initial histologic diagnosis and occurence of death. Pts at 500mg dose compared against Pts treated at 2000mg dose. Calculated using median
Time frame: Up to 3 years
Population: Phase 2 subjects only - does not include the 18 subjects from the safety run-in portion of study
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Arm 1 500mg (Safety Run In) | Overall Survival Based on Dose Level - Phase 2 | 17.4 months |
| ARM 2 1000mg (Safety run-in) | Overall Survival Based on Dose Level - Phase 2 | 20.8 months |
p-value: 0.495% CI: [0.5, 1.3]Regression, Cox